Leadership


  • The logo of the Food and Drug Administration is seen in a close-up view of the agency's website.
    Image attribution tooltip
    Mario Guti via Getty Images
    Image attribution tooltip

    Who is Dr. George Tidmarsh, the new director of CDER?

    Despite past criticism of public health policies, Tidmarsh recently praised the FDA and said he’ll focus on boosting review efficiencies.

    By Meagan Parrish and Michael Gibney • July 23, 2025
  • An exterior shot of the johnson and johnson logo in red outside the company's headquarters
    Image attribution tooltip
    Mario Tama / Staff via Getty Images
    Image attribution tooltip

    J&J accelerates past Stelara’s fall with better-than-expected portfolio growth

    Stelara is faltering due to biosimilar entries, but J&J execs demonstrate they were ready to fill the gap all along.

    By July 17, 2025
  • drug shopping cart Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Commercialization, marketing and social media

    As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

    By PharmaVoice staff
  • Capsule with hand cursor on yellow background
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A

    Need a DTC platform? Here’s how one company built its own.

    Currax Pharmaceuticals was ahead of the curve when it set up a direct access platform for its obesity med. 

    By July 14, 2025
  • Laboratory bottles with blue content and a syringe
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    First 90 Days

    As its cancer vaccine moves through the clinic, Transgene sets sights on manufacturing

    Simone Steiner recently joined the French company to set the stage for launch.  

    By July 9, 2025
  • Doctor holding patient's hands
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    First 90 Days

    A biopharma bolsters patient centricity and trial diversity goals through newly created role

    Ardelyx’s newly minted chief patient officer is infusing patient experiences into every element of the business.

    By Alexandra Pecci • July 1, 2025
  • AI brain
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    AI’s ‘massive transition’ in biopharma shapes leadership mindsets — tension and all

    The AI revolution is driving tension between new technology and the traditional approaches in drugmaking. Biopharma leaders are trying to navigate those turbulent waters.

    By July 1, 2025
  • An entrance to a National Institutes of Health building is lit by the sun on a clear day.
    Image attribution tooltip
    Grandbrothers via Getty Images
    Image attribution tooltip

    Biopharma is on edge about NIH funding cuts and what the future holds for research

    Proposed cuts to public funding for early science have led to an outcry in scientific circles. For biopharma leaders, the effects are still up in the air.

    By June 26, 2025
  • Mathai Mammen, CEO, Parabilis Medicines
    Image attribution tooltip
    Permission granted by Parabilis
    Image attribution tooltip
    Q&A

    How a Big Pharma veteran looks to stand out in biotech as a unique ‘drug hunter’

    J&J’s former head of R&D, now CEO of Parabilis Medicines, aims to remain above the biotech fray by taking on unique targets from which others have steered clear.

    By June 24, 2025
  • Highway Boston
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Biotech’s turning point: for every challenge, an opportunity in disguise

    As hurdles litter biotech’s future, forward-thinking leaders look for ways to leap to the other side.

    By June 20, 2025
  • diversity hands pill
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    How a patient group tackled research diversity for one disease and triggered change for pharma

    A policy win by the Foundation for Sarcoidosis Research has built momentum for other shifts that could bolster diversity in clinical trials.

    By June 17, 2025
  • Maya Martinez-Davis
    Image attribution tooltip
    Permission granted by Michael Moenning, Northlight Studio
    Image attribution tooltip
    Profile

    A day in the life of GSK’s U.S. president

    How Maya Martinez-Davis juggles life on the go during a busy year for new drug launches.

    By June 13, 2025
  • Syringes biotech
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Can ‘reputational pull’ save biotech from pharma’s image problem?

    A reputation is tough to build and easy to bruise. For drugmakers stuck in reputational limbo, embracing a clear direction and forward-thinking strategy can foster a rosier image.  

    By June 12, 2025
  • Capitol Hill lit up at night
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    Pharma’s wins and losses in the budget bill

    Key pharma reforms are up in the air as Republicans battle over their mammoth legislation that includes significant healthcare spending cuts.  

    By June 11, 2025
  • Ronny Gal, chief strategy and growth officer, Novartis
    Image attribution tooltip
    Permission granted by Novartis
    Image attribution tooltip
    Profile

    The former Wall Street analyst shaping Novartis’ big-picture strategy

    Ronny Gal, chief strategy and growth officer at Novartis, is guiding the company into a new era shaped by science-minded M&A and a slimmed-down pivot.

    By June 10, 2025
  • sad face bag
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Biotech CEO confidence hits rock bottom amid policy shifts

    A new survey sheds light on the way early-stage company leaders are grappling with regulatory headwinds.

    By June 4, 2025
  • Humans as technology and Human Job integration as employees being guided by robots.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    AI expertise is pharma’s next big hiring need — here’s what companies should look for

    The widespread hunt for candidates who are equally versed in tech and healthcare is making AI recruiting a challenge. 

    By Alexandra Pecci • May 29, 2025
  • Brain
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    With new Alzheimer’s blood test cleared, a potential vaccine could be on the horizon

    Nuravax and others are working on the next wave of Alzheimer’s treatments to catch the disease before symptoms arise.

    By May 28, 2025
  • A person in a suit sits at a desk with a microphone.
    Image attribution tooltip
    Chip Somodevilla via Getty Images
    Image attribution tooltip

    Turning the page: Novo’s CEO transition reflects Big Pharma’s era of change

    Turnover of the top execs at pharma giants like J&J, AbbVie and Merck in the last few years illustrates the seismic industry shifts that often accompany leadership changes.

    By May 22, 2025
  • Utpal Singh
    Image attribution tooltip
    Permission granted by Zealand Pharma
    Image attribution tooltip
    Q&A // First 90 Days

    Lilly’s former small molecule head makes the leap to a rising biotech in obesity

    Utpal Singh joined the peptide-focused biotech Zealand Pharma last month after it notched a massive obesity deal with Roche.

    By May 21, 2025
  • Amy Parison, CFO, Editas Medicine
    Image attribution tooltip
    Permission granted by Editas
    Image attribution tooltip
    Q&A // First 90 Days

    A new CFO tasked with taking ‘scrappy’ Editas from last year’s layoffs into new gene editing territory

    Amy Parison, who stepped into the lead financial role at the company in March, is managing Editas Medicine’s transition to a new gene editing platform while recovering from a major overhaul.

    By May 15, 2025
  • MAHA
    Image attribution tooltip
    Andrew Harnik via Getty Images
    Image attribution tooltip

    FDA’s future in MAHA hands: How leadership is changing the agency’s trajectory

    Who’s in, who’s out and which key positions are still left to be filled in an agency upended.

    By Alexandra Pecci • May 13, 2025
  • Chemotherapy cancer
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    With the breakneck speed of cancer breakthroughs, oncologists feel left behind. Can Big Pharma chime in?

    Community oncologists do their best to keep up with new treatments, but with the pace of cancer approvals, drugmakers need to team up with doctors on the front line.

    By May 13, 2025
  • Robert F. Kennedy Jr.
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip

    RFK Jr.’s autism fixation hearkens back to his stance on vaccines

    The head of HHS is seeking the “root causes” of autism spectrum disorder through a large government research project.

    By May 9, 2025
  • An Alnylam logo is displayed on a building in Cambridge, Massachusetts, on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/PharmaVoice
    Image attribution tooltip

    Alnylam keeps pushing the rare disease paradigm as RNAi promises even wider indications

    With another rare disease approval under its belt, Alnylam is still revving up the R&D engines for new indications.

    By May 8, 2025
  • Joaquin Duato
    Image attribution tooltip
    Kevin Dietsch via Getty Images
    Image attribution tooltip

    On tariffs and pricing, Big Pharma CEOs are waiting out the storm while planning for the worst

    Chief executives at the largest drugmakers in the world are confident tariffs and pricing measures won’t be a major problem. But they’re still poised for change.

    By May 6, 2025